Steroid sulfatase mediated growth Sof human MG-63 pre-osteoblastic cells.

Estrogen plays an important role in maintaining bone density. Postmenopausal women have low plasma estrogen, but have high levels of conjugated steroids, particularly estrone sulfate (E1S) and dehydroepiandrosterone sulfate (DHEAS). Conversion of these precursors to active estrogens may help maintain bone density in postmenopausal women. The enzyme steroid sulfatase (STS) converts sulfated steroids into active forms in peripheral tissues. STS occurs in bone, but little is known about its role in bone function. In this study, we investigated STS activity and expression in the human MG-63 pre-osteoblastic cell line. We also tested whether sulfated steroids can stimulate growth of these cells. MG-63 cells and microsomes both possessed STS activity, which was blocked by the STS inhibitors EMATE and 667 Coumate. Further evidence for STS in these cells was provided by RT-PCR, using STS specific primers, which resulted in cDNA products of the predicted size. We then tested for growth of MG-63 cells in the presence of estradiol-17ß, E1S and DHEAS. All three steroids stimulated MG-63 cell growth in a steroid-free basal medium. We also tested whether the cell growth induced by sulfated steroids could be blocked using a STS inhibitor (667 Coumate) or using an estrogen receptor blocker (ICI 182,780). Both compounds inhibited E1S-induced cell growth, indicating that E1S stimulates MG-63 cell growth through a mechanism involving both STS and the estrogen receptor. Finally, we demonstrated using RT-PCR that MG-63 cells contain mRNA for both estrogen receptor alpha and estrogen receptor beta. Our data reveal that STS is present in human pre-osteoblastic bone cells and that it can influence bone cell growth by converting inactive sulfated steroids to estrogenic forms that act via estrogen receptor alpha or beta.

Characterization of steroid sulfatase in the MC3T3-E1 mouse pre-osteoblastic cell line.

Regulation of bone density is partly dependent upon steroid hormones, with estrogens playing an important role. Inactive conjugated estrogens may serve as precursors to active estrogens, especially in post-menopausal women, via steroid sulfatase, which converts conjugated estrogens into unconjugated estrogens. The purpose of this study was to characterize steroid sulfatase in the MC3T3-E1 mouse pre-osteoblastic cell line. Enzyme conversion assays were performed on whole MC3T3-E1 cells in culture and on microsomes prepared by differential centrifugation. (3)H-E(1)S and (3)H-DHEAS were used as tracers, and radioinert E(1)S and DHEAS were used as substrate. Whole cells and microsomes exhibited steroid sulfatase activity, which was blocked by the specific inhibitor estrone-3-O-sulfamate (EMATE). The K(m) of steroid sulfatase in microsomes averaged 83 µM when using E(1)S as substrate and 64 µM when using DHEAS. Western blotting of MC3T3-E1 microsomes for steroid sulfatase was performed, after SDS-PAGE, using an antibody generated against a peptide based on a conserved region of steroid sulfatase. Western blotting revealed three bands of cross-reactivity, ranging from 50 to 79 kDa. Reverse transcriptase polymerase chain reaction (RT-PCR), using specific primers, resulted in a single cDNA band of the expected size (100 bp) and sequence, indicating the presence of steroid sulfatase mRNA. Growth assays revealed that the MC3T3-E1 cells were stimulated by estradiol-17ß, and also by estrone sulfate and DHEAS, revealing that the cells can use steroid sulfatase to produce active estrogens. Furthermore, growth of these cells in the presence of estradiol, estrone and estrone sulfate was inhibited by the estrogen receptor blocker ICI 182,780, indicating that stimulation of cell growth is mediated by the estrogen receptor. In our studies, four lines of evidence (enzyme activity, immunoassay, RT-PCR and growth assays) demonstrated the presence of steroid sulfatase in mouse MC3T3-E1 bone cells. The existence of steroid sulfatase in these pre-osteoblastic cells, along with the ability of sulfated steroids to promote their growth, suggest the possibility that this enzyme is involved in regulation of bone density in mice.

Steroid sulfatase activity in the rat ovary, cultured granulosa cells, and a granulosa cell line.

Direct production of gonadal steroids from sulfated adrenal androgens may be an important alternative or complementary pathway for ovarian steroidogenesis. The conversion of sulfated adrenal androgens, present in serum at micromolar concentrations in adult women, into unconjugated androgens or estrogens requires steroid sulfatase (STS) activity. STS activity has not been characterized in the rat ovary. Substantial STS activity was present in homogenates of rat ovaries, primary cultures of rat granulosa cells, and a granulosa cell line, as determined by conversion of radiolabeled estrone sulfate (E1S) to unconjugated estrone. The potent inhibitor estrone sulfamate eliminated the STS activity. Using E1S as a substrate with microsomes prepared from a granulosa cell line, the K(m) of STS activity was approximately 72 microM, a value in agreement with previously published data for rat STS. Therefore, ovarian cells possess STS and can remove the sulfate from adrenal androgens such as dehydroepiandrosterone sulfate (DHEA-S). Using DHEA-S as a steroidogenic substrate represents an alternative model for the production of ovarian steroids versus the "two cell, two gonadotropin" model of ovarian estrogen synthesis, whereby thecal cells produce androgens from substrate cholesterol and granulosa cells convert the androgens into estrogens. The relative contribution of STS activity to ovarian steroidogenesis remains unclear but may have important physiological and pathophysiological implications.

Development of (p-O-sulfamoyl)-N-alkanoyl-phenylalkyl amines as non-steroidal estrone sulfatase inhibitors.

Estrogen levels in breast tumors of postmenopausal women are as much as 10 times higher than estrogen levels in plasma, presumably due to in situ formation of estrogen. The major source of estrogen in breast cancer cells may be conversion of estrone sulfate to estrone by the enzyme estrone sulfatase. Thus, inhibitors of estrone sulfatase are potential agents for treatment of estrogen-dependent breast cancer. Several steroidal compounds have been developed that are potent estrone sulfatase inhibitors, most notably estrone-3-O-sulfamate. However, these compounds and their metabolites may have undesired effects, including estrogenicity. To avoid the problems associated with a potentially active steroid nucleus, we designed and synthesized a series of nonsteroidal estrone sulfatase inhibitors, the (p-O-sulfamoyl)-N-alkanoyl phenylalkyl amines. The compounds synthesized vary in the length of their alkanoyl chain and in the number of carbons separating the phenyl ring and the carbonyl carbon. The ability of these compounds to inhibit estrone sulfatase activity was tested using human placental microsomes and intact cultured human breast cancer cells. Estrogenicity was also evaluated, using growth of estrogen-dependent human breast cancer cells. All of the test compounds inhibited estrone sulfatase activity of human placental microsomes to some extent, with the most effective compound having an IC50 value of 72 nM. In general, compounds with longer alkanoyl chains (12-14 carbons) were more effective than those with shorter chains. The test compounds also inhibited estrone sulfatase activity in intact cultures of MDA-MB-231 human breast cancer cells. Again, the longer chain compounds were more effective. In both the placental and breast cancer cell sulfatase assays, the optimal distance between the phenyl ring and the carbonyl carbon was 1-2 carbons. The MCF-7 cell proliferation assay revealed that estrone and estrone-3-O-sulfamate were both estrogenic, but the (p-O-sulfamoyl)-N-alkanoyl phenylalkyl amines were not. Our data indicate the utility of (p-O-sulfamoyl)-N-alkanoyl phenyl alkylamines for inhibition of estrone sulfatase activity. Furthermore, our data support the concept that nonsteroidal estrone sulfatase inhibitors may be useful as therapeutic agents for estrogen-dependent breast cancers.

Synthesis and sulfatase inhibitory activities of (E)- and (Z)-4-hydroxytamoxifen sulfamates.

We report the development of (E)- and (Z)-4-hydroxytamoxifen sulfamates as estrone sulfatase inhibitors, potential therapeutic agents for the treatment of breast cancer. Both compounds competitively inhibit estrone sulfatase isolated from rat liver with apparent Ki of 35.9 microM for (E)-4-hydroxytamoxifen sulfamate and an apparent Ki of > 500 microM for the (Z) isomer.

Development of potent non-estrogenic estrone sulfatase inhibitors.

Estrogen levels in breast tumors of post-menopausal women are as much as 10 times higher than estrogen levels in plasma, presumably due to in situ formation of estrogen. The major source of estrogen in breast cancer cells may be conversion of estrone sulfate to estrone by the enzyme estrone sulfatase. Thus, inhibitors of estrone sulfatase have potential for the treatment of estrogen-dependent breast cancers. Several steroidal agents have been developed that are potent estrone sulfatase inhibitors, most notably estrone-3-O-sulfamate. These compounds may have undesired actions, especially estrogenicity. Recently, non-steroidal estrone sulfatase inhibitors have been designed that avoid the problems associated with an active steroid nucleus; however, these have not achieved the potency of estrone-3-O sulfamate. We have designed and synthesized a series of compounds, 17 beta-(N-alkylcarbamoyl)-estra-1,3,5(10)-trien-3-O-sulfamates (6a-d) and 17 beta-(N-alkanoyl)-estra-1,3,5(10)-trien-3-O-sulfamates (11a-d) that combine the structural features of the steroidal estrone sulfatase inhibitors with a membrane insertion region that should increase the affinity for the sulfatase enzyme and decrease the estrogenicity of the steroid. We tested the compounds for estrone sulfatase inhibition by measuring estrone sulfatase activity in intact cultures of human breast cancer cells (MDA-MB-231). We tested for estrogenicity by measuring growth of estrogen-dependent MCF-7 human breast cancer cells. All of the test compounds (10 nM) substantially inhibited estrogen sulfatase activity of intact MDA-MB-231 cells. Dose-response analysis indicated an IC50 of approximately 0.5 nM for two of the compounds (6a and 11a). In the test for estrogenicity, estrone and estrone-3-O-sulfamate significantly stimulated MCF-7 cell growth. In contrast, neither the 17 beta-(N-alkylcarbamoyl)-estra-1,3,5,(10)-trien-3-O-sulfamates++ + nor the 17 beta-(N)-alkanoyl)-estra-1,3,5,(10)-trien-3-O-sulfamates stimulated growth of MCF-7 cells at a concentration of 1 microM, indicating that they are not estrogenic at levels 2000 times greater than their IC50 for estrone sulfatase. Our data indicate the utility of the new compounds for inhibition of breast cancer cell estrone sulfatase activity. Further, our data support the concept that estrone sulfatase inhibitors may be useful as therapeutic agents for estrogen-dependent breast cancers.

Inhibition of estrone sulfatase and proliferation of human breast cancer cells by nonsteroidal (p-O-sulfamoyl)-N-alkanoyl tyramines.

Estrogen levels in breast tumors of postmenopausal women are as much as 10 times higher than estrogen levels in plasma, presumably due to in situ formation of estrogen. The major source of estrogen in breast cancer cells may be the conversion of estrone sulfate to estrone by the enzyme estrone sulfatase. Thus, inhibitors of estrone sulfatase have potential for the treatment of estrogen-dependent breast cancers. Several steroidal agents have been developed that are potent estrone sulfatase inhibitors, most notably estrone-3-O-sulfamate. However, these compounds may be metabolized to forms that have undesired actions, including estrogenicity. To avoid the problems associated with a potentially active steroid nucleus, we designed and synthesized a series of (p-O-sulfamoyl)-N-alkanoyl tyramines as nonsteroidal estrone sulfatase inhibitors. These nine compounds differ in the length of their alkanoyl chains. We tested the ability of the (p-O-sulfamoyl)-N-alkanoyl tyramines to inhibit: (a) estrone sulfatase activity in intact cultures of human breast cancer cells (MDA-MB-231); and (b) the growth of estrogen-dependent human breast cancer cells (MCF-7). All of the test compounds (1 microM) inhibited the estrone sulfatase activity of intact MDA-MB-231 cells; however, compounds with a longer alkanoyl chain were more effective than those with a shorter chain. Dose-response analysis indicated an IC50 of 350 nM for (p-O-sulfamoyl)-N-tetradecanoyl tyramine for the inhibition of MDA-MB-231 estrone sulfatase activity. The inhibition of MDA-MB-231 cell estrone sulfatase activity by this compound was found to be irreversible. Cell proliferation assays involved the treatment of estrogen-deprived MCF-7 cells with test compounds (10 microM) in the presence of estrone sulfate (1 microM) as the only source of estrogen. All compounds inhibited cell proliferation to some extent, but the longer-chain analogues again were more effective. Dose-response analysis indicated an IC50 of 38 nM for (p-O-sulfamoyl)-N-tetradecanoyl tyramine for the inhibition of MCF-7 cell proliferation. Our data indicate the utility of (p-O-sulfamoyl)-N-alkanoyl tyramines for the inhibition of breast cancer cell estrone sulfatase activity. Furthermore, our data support the concept that nonsteroidal estrone sulfatase inhibitors may be useful as therapeutic agents for estrogen-dependent breast cancers.

Inhibition of placental estrone sulfatase activity and MCF-7 breast cancer cell proliferation by estrone-3-amino derivatives.

Estrogen levels in breast tumors of post-menopausal women are as much as 10 times higher than in plasma, presumably due to in situ formation of estrogen. Several lines of evidence indicate that the major source of estrogen in breast cancer cells may be from conversion of estrone sulfate to estrone by the enzyme estrone sulfatase. Inhibitors of estrone sulfatase may thus be potential agents for the treatment of estrogen-dependent breast cancer. We designed and synthesized a series of estrone-3-amino derivatives as potential estrone sulfatase inhibitors. We tested the inhibitory potential of these compounds using human placental microsomes, which contain a substantial amount of estrone sulfatase activity. Several compounds in the series significantly inhibited estrone sulfatase activity of the human placental microsomes when present at 10 microM. The IC50 for the estrone-3-amino compounds ranged from 8.7 to 14.6 microM. We next tested the ability of the estrone-3-amino derivatives to inhibit growth of the estrogen-dependent MCF-7 breast cancer cell line. MCF-7 cells showed substantial proliferation in the presence of 100 nM estrone sulfate in estrogen-free media, indicating that the cells were capable of converting estrone sulfate into estrone. The proliferative effect of estrone sulfate (1 microM) was significantly blocked by the estrone-3-amino derivatives at 10 microM. The magnitude of MCF-7 cell inhibition resulting from treatment with the estrone-3 amino compounds was similar to or exceeded that of Danazol, but was less than the level resulting from treatment with estrone sulfamate. Using data from all of the compounds tested, inhibition of MCF-7 cell proliferation was positively correlated with inhibition of placental estrone sulfatase activity, suggesting that the reduction in cell growth was attributable to the blockade of sulfatase activity. In support of this, there was no relationship between inhibition of estrone sulfatase activity and inhibition of cell growth when the estrogen-independent cell line MDA-MB-231 was used. Our results indicate the possible utility of estrone-3-amino derivatives for inhibition of estrone sulfatase activity. Further, our data support the concept that estrone sulfatase inhibitors may be useful as therapeutic agents for estrogen-dependent breast cancers.

Estrogen downregulation of albumin and a 170-kDa serum protein in the turtle, Trachemys scripta.

We examined changes in serum protein composition after estradiol-17 beta treatment of ovariectomized female Trachemys scripta, with the objective of identifying proteins that are repressed by estrogen. The experimental protocol was validated by measuring serum estradiol-17 beta levels with a specific radioimmunoassay. Control turtle sera contained little or no estradiol-17 beta (mean = 25.8 pg/ml) while estrogen-treated turtle sera had elevated estradiol-17 beta levels (mean = 333.3 pg/ml). Estrogen treatment resulted in a significant increase in serum protein concentration. The increase was due largely to a 213-kDa protein that was abundant in estrogen-treated animal sera but was low or absent in control animal sera. This protein was identified as vitellogenin based on its biochemical characteristics (molecular weight, elution profile from DEAE, precipitation in the presence of Mg2+/EDTA). Several proteins were decreased in the sera of estrogen-treated animals. One of these had a molecular weight of 66 kDa and was determined to be serum albumin. This protein crossreacted in Western blot analyses with polyclonal antisera against chicken and human serum albumins. Also, amino acid sequence analysis revealed substantial homology between the 66-kDa turtle protein and serum albumins from other vertebrate species. Another protein decreased by estrogen treatment had a molecular weight of 170 kDa. Both albumin and the 170-kDa protein were reduced in estrogen-treated turtles to levels about 50% of those present in control turtles. Using [35S]methionine-labeling and denaturing (SDS) polyacrylamide gel electrophoresis, we detected the presence of newly labeled albumin and the 170-kDa protein in T. scripta liver cube cultures, indicating that these proteins are derived from the liver. Data from this study reveal that estrogen downregulates several serum proteins in T. scripta, while upregulating serum vitellogenin. The response to estrogen in this reptile is similar to that in the amphibian Xenopus laevis, suggesting that estrogen downregulation of serum proteins during vitellogenesis may be widespread among oviparous vertebrates.

Estrogenicity, antiestrogenicity and estrone sulfatase inhibition of estrone-3-amine and estrone-3-thiol.

Estrogen levels in breast tumors of post-menopausal women are at least 10 times higher than estrogen levels in plasma. The high level of estrogen in these tumors is postulated to be due to in situ formation of estrogen, possibly through conversion of estrone sulfate to estrone by the enzyme estrone sulfatase. Thus, inhibitors of estrone sulfatase are potential agents for the treatment of hormone-dependent breast cancers. We designed and synthesized a series of estra-1,3,5(10)triene-17-one, 3-amino and estra-1,3,5(10)triene-17-one, 3-thio derivatives. We have shown previously that several of these compounds substantially inhibit estrone sulfatase, exceeding Danazol in their inhibitory activity. However, little is known about the metabolism of these compounds and the possible effects of their metabolites in vivo. Two probable metabolites of the synthetic estrone analogs are estra-1,3,5(10)triene-17-one, 3-amine (E1-NH2), and estra-1,3,5(10)triene-17-one, 3-thiol (E1-SH). We tested these two compounds for estrogenicity, antiestrogenicity and inhibition of estrone sulfatase activity using a combination of in vivo and in vitro assays. The ovariectomized rat uterine weight gain assay was used to test for estrogenicity. Neither E1-NH2 nor E1-SH were estrogenic, as indicated by a lack of uterine weight gain when given at 25 micrograms/day for 7 days. The test compounds also were not antiestrogenic, in that they did not block estrone-induced uterine weight gain when given (100 micrograms/day) simultaneously with estrone (2 micrograms/day). Both compounds showed low affinity for the estrogen receptor. Using rat uterine cytosol as a source of estrogen receptor, the compounds displaced only a small percentage of [3H]estradiol binding, even when present at 1000-fold excess. Inhibition of estrone sulfatase activity was tested using human placental microsomes as a source of estrone sulfatase. E1-NH2 and E1SH showed very low levels of estrone sulfatase inhibition (15.1 and 9.8%, respectively) under conditions where Danazol showed more than 60% inhibition. Our results indicate that neither of these two compounds would present significant problems if they were the primary metabolite in a treatment involving estrone sulfatase inhibition of estrogen-dependent breast cancer.

Progesterone downregulates progesterone receptor, but not estrogen receptor, in the estrogen-primed oviduct of a turtle (Trachemys scripta).

Progesterone downregulates nuclear progesterone receptor (Rp) and estrogen receptor (Re) in the estrogen-primed mammalian uterus and chick oviduct. We sought to determine if this downregulation mechanism is operative in the turtle oviduct. Female turtles were primed for 4 days with 17-beta-estradiol, after which progesterone (5 mg) was administered by injection every 24 h. Re and Rp levels in progesterone-treated and control turtle oviducts were measured by [3H]steroid-binding assays (pyridoxal 5' phosphate method) at 12, 24, 48 and 72 hr after initial progesterone treatment. Serum progesterone levels of progesterone-treated turtles increased only slightly from 0 hr (0.3 ng/ml) to 12 hr (0.6 ng/ml) after progesterone administration, increased considerably by 24 hr (5.3 ng/ml), and remained elevated (6-8 ng/ml) through 72 hr. Cytosol and nuclear Rp levels of estrogen-primed turtle oviducts showed distinct seasonal variation, with Rp levels higher in spring and summer months than in winter months. There was no seasonal variation in Re levels. Both cytosol and nuclear Rp responded to progesterone treatment. Cytosol Rp levels of progesterone-treated oviducts were significantly reduced below control levels by 12 hr after progesterone administration and remained low through 72 hr. Nuclear Rp levels of progesterone-treated oviducts showed no change at 12 hr, increased at 24 hr and then dropped at 48 and 72 hr. However, progesterone did not downregulate Re in the turtle oviduct.(ABSTRACT TRUNCATED AT 250 WORDS)

Serum corticosteroid-binding globulin (CBG) and hepatic CBG mRNA relationships during hamster pregnancy: contribution of decidualization.

We measured serum corticosteroid-binding globulin (CBG) and hepatic CBG mRNA from individual hamsters throughout pregnancy and during decidualization. Serum CBG levels were determined by 3H-cortisol binding assay, and hepatic CBG mRNA levels were measured by Northern blots and solution hybridization assays, using a 32P-labeled cRNA probe derived from a rat CBG cDNA. There was a positive relationship between hepatic CBG mRNA levels and serum CBG levels during pregnancy. Both parameters increased significantly from the time of mating (cycle Day 4) to pregnancy Day 4, showing that CBG synthesis and secretion increased prior to implantation (Day 4). After implantation, serum CBG and hepatic CBG mRNA rose further from pregnancy Day 4 to a peak on Day 14, then decreased before parturition on Day 16. The prepartum decline in hepatic CBG mRNA preceded the fall in serum CBG. Decidualization on pseudopregnancy Day 4 resulted in an increase in serum CBG and hepatic CBG mRNA. Hepatic CBG mRNA increased from Day 5 to Day 7, and serum CBG increased progressively from Day 5 through Day 9 after uterine decidualization in the hamster. The present results demonstrate that the pattern of serum CBG observed in the pregnant hamster follows closely that of hepatic CBG mRNA. A signal emanating from uterine decidual tissue appears to be important in the regulation of hepatic CBG synthesis and secretion during midpregnancy, but other unknown factors appear to be involved in controlling CBG during the early and late stages of pregnancy.

Characterization of the corticosteroid-binding globulin messenger ribonucleic acid response in the pregnant hamster.

In this study we measured corticosteroid-binding globulin (CBG) mRNA levels in liver and various nonhepatic tissues of pregnant and nonpregnant hamsters. The N-terminal amino acid sequence (37 residues) of hamster CBG was determined and compared with published cDNA-deduced sequence information for rat and human CBG. Hamster CBG showed considerable sequence homology with both rat (70%) and human (59%) CBG. Because of the high level of homology, we were able to use a cRNA prepared from a rat CBG cDNA as a probe in Northern blot and solution hybridization analyses. Northern blots of hamster and rat liver RNA extracts revealed that the rat CBG cDNA probe hybridized to RNAs that were the same size in rats and hamsters. Further, the Northern blot showed that pregnant hamster liver contained substantially more CBG mRNA than nonpregnant hamster liver. The relative amounts of CBG mRNA in pregnant and nonpregnant hamster livers were compared using a solution hybridization assay. Slope-ratio analysis of the hybridization data revealed that pregnant hamster liver (day 14) contained 40-fold more CBG mRNA than nonpregnant hamster liver. When other tissues (kidney, spleen, small intestine, and decidual tissue) were assayed for CBG mRNA, a small amount of hybridization was detected by solution hybridization. However, Northern blot analysis of RNA extracts from nonhepatic tissues showed that the hybridizable sequences did not migrate at the same position as mature CBG mRNA. These results indicate that the observed increase in serum CBG during hamster pregnancy is largely attributable to an increase in hepatic CBG mRNA.

Characterization of the corticosteroid-binding globulin response to decidualization in the hamster.

We sought to characterize the relationship between the decidualized uterus and circulating corticosteroid-binding globulin (CBG) levels during pseudopregnancy in the hamster. Blood CBG levels (as measured by [3H] cortisol binding) averaged 11-fold greater for decidualized hamsters than for sham-operated controls on day 8 of pseudopregnancy (PSP). We used sequential blood sampling from individual hamsters to monitor changes in CBG content after decidualization. The increase in blood CBG after decidualization was rapid, as evidenced by a significant difference in CBG content between sham-operated and decidualized groups within 24 h after surgery. We varied the extent of uterine traumatization to induce differing amounts of decidual tissue. Regardless of the amount of decidual tissue, all decidualized hamsters showed a significant increase in blood CBG; however, there was a dose-dependent relationship between the amount of decidual tissue formed and the magnitude of the CBG response. We used hysterectomy (on PSP day 6, after decidualization on PSP day 4) to determine if removal of the decidualized uterus influenced the duration of the CBG response. Bilateral hysterectomy blocked further increases in blood CBG, whereas in control animals (unilateral hysterectomy) blood CBG continued to increase after surgery. Thus, once the CBG response is initiated, the decidualized uterus is necessary to maintain elevated CBG levels. The findings in this study provide further evidence for the presence of a decidua-hepatic endocrine axis that appears to be responsible for elevation of circulating CBG levels during early pregnancy in the hamster.

Progesterone down-regulation of nuclear estrogen receptor: a fundamental mechanism in birds and mammals.

Progesterone is known to selectively down-regulate nuclear estrogen receptor (Re) in the mammalian uterus, and this process is functionally related to embryo retention. It is unclear if this mechanism is operative in the chick oviduct, where egg retention does not occur. We investigated the regulation of Re by progesterone in a mammalian model (proestrous hamster uterus) and an avian model (DES-primed chick oviduct), under the same assay conditions, in an effort to compare progesterone action in viviparous and oviparous species. Nuclear and cytosol estrogen receptor were measured with an assay employing pyridoxal 5'-phosphate (PLP). The PLP assay has the advantage of allowing exchange at low temperature, which results in improved receptor recovery, especially from the nuclear fraction. Parallel studies were done under two different hormonal settings, estrogen primed and estrogen + progesterone primed. Experiments were: (1) response of Re to acute progesterone treatment (5 mg progesterone, 4 hr) in estrogen-primed preparation, (2) time course of the Re down-regulation response (4, 8, and 12 hr after progesterone treatment), and (3) recovery of Re after progesterone withdrawal in estrogen + progesterone-primed preparation. Chick oviduct contained little cytosol Re (0.96 +/- 0.32 pmol/g tissue) compared to hamster uterus (4.27 +/- 0.15 pmol/g tissue), and progesterone treatment had no effect on cytosol Re levels in either species. Nuclear Re levels were similar for chick oviduct (2.68 +/- 0.14 pmol/g tissue) and hamster uterus (2.64 +/- 0.14 pmol/g tissue). Progesterone treatment reduced nuclear Re levels in both the hamster uterus and chick oviduct to about 50% of control levels. In the chick oviduct, down-regulation was transient, as evidenced by complete recovery of nuclear Re to control levels by 12 hr after progesterone administration. In the estrogen + progesterone-primed chick oviduct, nuclear Re increased within 6 hr after progesterone withdrawal and approached maximal levels by 12 hr. These data indicate that progesterone rapidly and selectively down-regulates the nuclear form of Re in the chick oviduct as in the hamster uterus. Thus, the regulation of Re by progesterone appears to be similar in the mammalian uterus and the chick oviduct, despite the basic differences in reproductive strategy between birds and mammals.(ABSTRACT TRUNCATED AT 400 WORDS)

Hamster uterine tissues accumulate corticosteroid-binding globulin during decidualization.

Although corticosteroid-binding globulin (CBG) is known to be a serum steroid-binding protein, its function outside of the vascular space is not well understood. To prove an extravascular role for CBG, it must first be established that CBG occurs in steroid target tissues. We sought information on the occurrence of CBG in the cytosol, nuclear, and membrane fractions of 6 tissues during decidualization in the hamster. Our objectives were to determine if CBG is distributed in a tissue-specific manner, and to investigate the relationship between serum CBG and tissue CBG. Hamsters were given progesterone pellets s.c. on cycle Day 1 and decidualization was induced on Day 4. A 3H-cortisol-binding assay, which distinguished between CBG and glucocorticoid receptor, was used to determine CGB levels in the serum and in the cytosol, nuclear, and membrane fractions of deciduoma, myometrium, liver, kidney, muscle, and small intestine. Cytosol CBG accounted for greater than 97% of the total CBG detected in all tissues except liver, where nuclei contained 11% of the measurable CBG. For all cell fractions, CBG levels showed consistent tissue-specific differences. Cytosol CBG was highest in deciduoma and myometrium, 2-fold less in liver and kidney, and 5-fold less in muscle and small intestine. Nuclear CBG concentration was greatest in liver and approximately 10-fold less in other tissues, except for small intestine, where nuclear CBG was undetectable. Membrane CBG was highest in liver, 5-fold less in deciduoma, 10-fold less in myometrium, and about 20-fold less in other tissues. Serum CBG increased 7-fold from Day 4 to Day 9 in decidualized hamsters, but not in nondecidualized sham-operated hamsters. In all tissues, serum CBG was correlated with cytosol CBG. The high levels of CBG in uterine tissues were not the result of serum contamination because whole-body perfusion with buffered saline failed to remove the majority of cytosol CBG under conditions where over 70% of 51Cr-labeled red blood cells were removed. The identity of uterine cytosol CBG with serum CBG was established by ion-exchange chromatography (O-(diethylaminoethyl)-cellulose) and by immunoprecipitation with an antibody generated against serum CBG. These data demonstrate that uterine tissues accumulate substantial amounts of CBG during decidualization, thus raising the possibility of a functional role of CBG in uterine tissues during early pregnancy.

Pattern of ovarian progesterone secretion during the luteal phase of the ovine estrous cycle.

Pulsatile secretion of progesterone has been observed during the late luteal phase of the menstrual cycle in the rhesus monkey and human. As the luteal phase progresses in each of these species, there is a pattern of decreased frequency and increased amplitude of progesterone pulses. The present study was designed to determine the pattern of progesterone secretion during the late luteal phase (Days 10-16) of the normal ovine estrous cycle. Five unanesthetized ewes, each bearing an indwelling cannula in the utero-ovarian vein, were bled every 15 min from 0800 h on Day 10 through 0800 h on Day 16 of the estrous cycle. With the computer program PULSAR, it was determined that progesterone secretion was episodic, with pulsations observed on all days. Analysis of variance was used to determine differences in frequency, amplitude, and interpeak interval (IPI) of progesterone pulses among ewes and days. The ewes averaged 8.0 +/- 0.63 pulses of progesterone per 24 h. Mean frequency of pulses was not different between days but showed differences between ewes. Mean amplitude of progesterone pulses was 7.0 +/- 0.27 ng/ml, with no differences observed either between days or between ewes. Mean IPI was 197 +/- 7.1 min, and, like frequency, the IPI was not different between days, but varied between ewes. No consistent temporal relationship was found between progesterone pulses and luteinizing hormone (LH), as determined by bioassay and radioimmunoassay, on Day 14 of the cycle in one ewe. The results indicate that progesterone secretion is episodic during the luteal phase of the ovine estrous cycle and is independent of LH pulses.(ABSTRACT TRUNCATED AT 250 WORDS)

Decidual cell function: evidence for a role in the regulation of serum CBG and a 60 kDa protein during early pregnancy in the hamster.

Several serum proteins increase in titer during pregnancy. We tested the hypothesis that decidual cells may signal the production of certain serum proteins in the hamster. Measurement of serum CBG by equilibrium binding using either [3H]-progesterone or [3H]-cortisol in conjection with ion exchange chromatography showed that decidualization increased CBG levels. Two-dimensional gel electrophoresis revealed that a 60 kDa++ protein increases markedly in the serum of the hormonally pseudopregnant (PSP) animal soon after artificial induction of decidualization on PSP day 4. The 60 kDa serum protein remains low in the nondecidualized PSP animal, but it increases in the pregnant animal. A photoaffinity labeling procedure was used to covalently bind [3H]-androstadienolone to CBG. Fluorography of 2D gels run under denaturing conditions established that the 60 kDa protein did not bind steroid as did CBG (69 kDa). To determine whether decidual cells could induce the 60 kDa and CBG proteins, different numbers of decidual cells were injected IP into PSP recipients. A single injection of 50 x 10(6) decidual cells induced both serum proteins within 48h, whereas the same number of hamster fetal cells was ineffective. Thus, these results demonstrate that hamster decidual cells induce a 60 kDa protein of unknown function and serum CBG. Since the decidual cell itself does not appear to be the source of either protein, it follows that the decidual cell signals the synthesis and secretion of these proteins elsewhere in the body, most likely in the liver. To our knowledge, this is the first demonstration that the decidual cell regulates serum CBG and other proteins in this manner.